Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00628
|
|||||
| Drug Name |
Captopril
|
|||||
| Synonyms |
(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; 3-Mercapto-2-methylpropionyl-proline; Acediur; Aceplus; Acepress; Acepril; Alopresin; Apopril; Apopril (TN); Asisten; C 4042; Capoten; Capoten (TN); Captolane; Captopril (JP15/USP/INN); Captopril [USAN:INN:BAN:JAN]; Captoprilum; Captoprilum [INN-Latin]; Captopryl; Captoril; Captril; Cesplon; D-2-Methyl-3-mercaptopropanoyl-L-proline; D-3-Mercapto-2-methylpropanoyl-L-proline; D-3-Mercapto-2-methylpropionylproline; Dilabar; Garranil; Garranil (discontinued); Hipertil; Hypertil; Isopresol; L-Captopril; Lopirin; Lopirin [Switzerland]; Lopril; MCO; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline;(2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; SA 333; SQ 14,225; SQ 14225; SQ-14,225; SQ-14,534; SQ-14225; SQ-14534; Tenosbon; Tensiomin; Tensobon; Tensoprel; X8Z; [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | High blood pressure [ICD11: BA00] | Approved | [1] | |||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C9H15NO3S
|
|||||
| Canonical SMILES |
CC(CS)C(=O)N1CCCC1C(=O)O
|
|||||
| InChI |
InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
|
|||||
| InChIKey |
FAKRSMQSSFJEIM-RQJHMYQMSA-N
|
|||||
| CAS Number |
CAS 62571-86-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 217.29 | Topological Polar Surface Area | 58.6 | ||
| Heavy Atom Count | 14 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
0.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321204
, 11110941
, 11335383
, 11360622
, 11363582
, 11366144
, 11368706
, 11372295
, 11374460
, 11376868
, 11461594
, 11484758
, 11489027
, 11491203
, 11492626
, 11494502
, 11533495
, 12013747
, 14797867
, 15195876
, 17404865
, 22391411
, 24278149
, 24893111
, 26612024
, 26679590
, 26747043
, 26747044
, 26751563
, 26758381
, 3154070
, 34709396
, 46392259
, 46487953
, 46506879
, 47365058
, 47440133
, 47515193
, 47515194
, 47515195
, 47736347
, 47736348
, 47959603
, 49698307
, 7847317
, 7978852
, 8149632
, 8178487
, 823180
, 855925
|
|||||
| ChEBI ID |
ChEBI:3380
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
| References | ||||||
| 1 | Captopril was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Membrane transporters in drug development. Nat Rev Drug Discov. 2010 Mar;9(3):215-36. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.